Eli Lilly’s Jaypirca pushes into first-line CLL, but commercial upside may be limited

Jaypirca; pirtobrutinib; Eli Lilly; chronic lymphocytic leukemia; CLL; small lymphocytic lymphoma; SLL; first-line treatment; second-line treatment; Bruin-CLL-314; Imbruvica; ibrutinib; BTK inhibitor; progression-free survival; FDA traditional approval; label expansion; market ceiling; oncology strategy

Eisai Expands Leqembi Subcutaneous Label, Accelerates Early U.S. Launch Progress for Alzheimer’s Disease

Eisai; Leqembi; subcutaneous autoinjector; label expansion; Supplemental Biologics License Application (sBLA); FDA; maintenance dosing; starting dose; early Alzheimer’s disease; at-home injection; launch progress

Oura Health’s Healthcare Ambitions Materialize with $11 Billion Valuation and Expansion Plans

Oura; Oura Ring; healthcare technology; Series E funding; $11B valuation; AI health features; wearables market; global expansion; preventive health; personalized health services

Lilly Commits $1.2 Billion to Expand GLP-1 Pill Manufacturing Facility in Puerto Rico

Eli Lilly; Puerto Rico; GLP-1 receptor agonist; orforglipron; manufacturing expansion; oral medicines; investment; Carolina; pharmaceutical production; U.S. supply chain

Cytek Biosciences Deepens Commitment to Expanding Access to Flow Cytometry

Cytek Biosciences; flow cytometry; access expansion; ISAC collaboration; instrument awards; research grants; Full Spectrum Profiling (FSP); European expansion; Amsterdam facility; cell analysis

Ypsomed Invests $248 Million to Establish First U.S. Manufacturing Site in North Carolina

Ypsomed; manufacturing expansion; U.S. facility; Holly Springs; North Carolina; CHF 200 million; self-injection systems; job creation; global growth strategy; medical technology